当前位置: 首页 >> 检索结果
790. Hypertrophic cardiomyopathy secondary to hydroxychloroquine toxicity in a patient with rheumatoid arthritis.
作者: Iside Cartella.;Matteo Palazzini.;Domenico Sirico.;Andrea Buono.;Duccio Petrella.;Fabrizio Oliva.;Andrea Garascia.;Enrico Ammirati.
来源: Lancet. 2024年404卷10462期1560页 791. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
作者: Amanda B Payne.;Janet A Watts.;Patrick K Mitchell.;Kristin Dascomb.;Stephanie A Irving.;Nicola P Klein.;Shaun J Grannis.;Toan C Ong.;Sarah W Ball.;Malini B DeSilva.;Karthik Natarajan.;Tamara Sheffield.;Daniel Bride.;Julie Arndorfer.;Allison L Naleway.;Padma Koppolu.;Bruce Fireman.;Ousseny Zerbo.;Julius Timbol.;Kristin Goddard.;Brian E Dixon.;William F Fadel.;Colin Rogerson.;Katie S Allen.;Suchitra Rao.;David Mayer.;Michelle Barron.;Sarah E Reese.;Elizabeth A K Rowley.;Morgan Najdowski.;Allison Avrich Ciesla.;Josephine Mak.;Emily L Reeves.;Omobosola O Akinsete.;Charlene E McEvoy.;Inih J Essien.;Mark W Tenforde.;Katherine E Fleming-Dutra.;Ruth Link-Gelles.
来源: Lancet. 2024年404卷10462期1547-1559页
Respiratory syncytial virus vaccines first recommended for use during 2023 were efficacious against lower respiratory tract disease in clinical trials. Limited real-world data regarding respiratory syncytial virus vaccine effectiveness are available. To inform vaccine policy and address gaps in evidence from the clinical trials, we aimed to assess the effectiveness against respiratory syncytial virus-associated hospitalisations and emergency department encounters among adults aged at least 60 years.
792. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.
作者: Anthony Rodgers.;Abdul Salam.;Aletta E Schutte.;William C Cushman.;H Asita de Silva.;Gian Luca Di Tanna.;Diederick E Grobbee.;Krzysztof Narkiewicz.;Dike B Ojji.;Neil R Poulter.;Markus P Schlaich.;Suzanne Oparil.;Wilko Spiering.;Bryan Williams.;Jackson T Wright.;P Lakshman.;W Uluwattage.;P Hay.;T Pereira.;N Amarasena.;G Ranasinghe.;Chris Gianacas.;Mathangi Shanthakumar.;Xiaoqiu Liu.;Nelson Wang.;Sonali R Gnanenthiran.;Paul K Whelton.; .
来源: Lancet. 2024年404卷10462期1536-1546页
Single-pill combinations (SPCs) of three low-dose antihypertensive drugs can improve hypertension control but are not widely available. A key issue for any combination product is the contribution of each component to efficacy and tolerability. This trial compared a new triple SPC called GMRx2, containing telmisartan, amlodipine, and indapamide, with dual combinations of components for efficacy and safety.
|